Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor α and glucocorticoid induced apoptosis

Annals of the Rheumatic Diseases

Volumn 66, Issue 10, 2007, Pages 1289-1295

  Oerlemans, Ruud ^a   Vink, Josefien ^a   Dijkmans, Ben A C ^a   Assaraf, Yehuda G ^b   Van Miltenburg, Marjolein ^a   Van Der Heijden, Joost ^a   Ifergan, Ilan ^b   Lems, Willem F ^a   Scheper, Rik J ^a   Kaspers, Gertjan J L ^a   Cloos, Jacqueline ^a   Jansen, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISOLONE; SALAZOSULFAPYRIDINE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; CELL LINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; MACROPHAGES; MONOCYTES; NF-KAPPA B; PREDNISOLONE; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; SULFASALAZINE; U937 CELLS; UP-REGULATION;

EID: 34848897456     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.060509     Document Type: Article

References (45)

1. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
2. Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8:1681-94.
3. Kaspers GJ, Veerman AJ. Clinical significance of cellular drug resistance in childhood leukemia. Recent Results Cancer Res 2003;161:196-220.
4. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-59.
5. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24:488- 522.
6. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002;67:529-34.
7. Kofler R. The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 2000;114:1-7.
8. McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998;12:45-56.
9. Haarman EG, Kaspers GJ, Veerman AJ. Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation. Br J Haematol 2003;120:919-29.
10. Pujols L, Mullol J, Roca-Ferrer J, Torrego A, Xaubet A, Cidlowski JA, et al. Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. Am J Physiol Cell Physiol 2002;283:C1324-31.
11. Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, et al. High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med 2001;193:585-93.
12. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001;98:6865-70.
13. Haarman EG, Kaspers GJ, Pieters R, Rottier MM, Veerman AJ. Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia 2004;18:530-7.
14. Kaspers GJ, Pieters R, Van Zantwijk CH, van Wering ER, Van der Does-Van den Berg, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998;92:259-66.
15. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, Van Zantwijk CH, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-51.
16. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339-46.
17. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology (Oxford) 2004;43:1337-45.
18. Kofler R, Schmidt S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003;178:19-27.
19. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ, 2004;11(Suppl 1), S45-55.
20. Webster JI, Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J Steroid Biochem Mol Biol 2002;82:277-88.
21. Kaspers GJ, Pieters R, Klumper E, de Waal FC, Veerman AJ. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 1994;13:187-201.
22. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
23. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
24. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, van ZD, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
25. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
26. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000;119:1209-18.
27. Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T- lymphocytes by sulfasalazine. Br J Pharmacol 1999;128:1361-9.
28. Van der Heijden J, de Jong MC, Dijkmans BAC, Lems WF, Oerlemans R, Kathmann GA, et al. Acquired resistance of human T cells to sulphasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004;63:131-7.
29. Van der Heijden J, de Jong MC, Dijkmans BAC, Lems WF, Oerlemans R, Kathmann GA, et al. Development of sulphasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 2004;63:138- 43.
30. de Bruin M, Peters GJ, Oerlemans R, Assaraf YG, Masterson AJ, Adema AD, et al. Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells. Mol Pharmacol 2004;66:1054-60.
31. Smedegard G, Bjork J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol, 1995;34(Suppl 2), 7-15.
32. Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ. Inhibition of folate-dependent enzymes by non-steroidal anti- inflammatory drugs. Biochem J 1992;282:197-202.
33. Rodenburg RJ, Ganga A, van Lent PL, van de Putte LB, van Venrooij WJ. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 2000;43:1941-50.
34. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
35. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
36. Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA. Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001;13:177- 83.
37. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001;28:845-53.
38. Franzoso G, Biswas P, Poli G, Carlson LM, Brown KD, Tomita-Yamaguchi M, et al. A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. J Exp Med 1994;180:1445-56.
39. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000;14:399-402.
40. Lipford JR, Deshaies RJ. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. Nat Cell Biol 2003;5:845-50.
41. Deroo BJ, Rentsch C, Sampath S, Young J, DeFranco DB, Archer TK. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol 2002;22:4113-23.
42. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001;276:42714-21.
43. Jacobson A, Melhus H, Wadelius M. Can mutations in ELA2, neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis? BMC Blood Disord 2004;4:5.
44. Perkins ND. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 2000;25:434-40.
45. Frearson R, Cassidy T, Newton J. Polymyalgia rheumatica and temporal arteritis: evidence and guidelines for diagnosis and management in older people. Age Ageing 2003;32:370-4.